Zydus Cadila gets final approval from USFDA for Clobazam Tablets

23 Oct 2018 Evaluate

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Clobazam Tablets, (US RLD-ONFI Tablet), 10 mg and 20 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

Clobazam is used in combination with other medications to treat seizures caused by a paediatric epilepsy syndrome (termed as Lennox-Gastaut syndrome) that also causes developmental and behavioural problems.

The group now has 224 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

880.20 12.40 (1.43%)
19-Jan-2026 14:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1680.90
Dr. Reddys Lab 1172.55
Cipla 1397.70
Zydus Lifesciences 880.20
Lupin 2175.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×